Strategic Acquisition Rigel Pharmaceuticals recently acquired assets from Blueprint Medicines Corporation for $118 million, indicating a potential expansion of their product portfolio and market presence in the biotechnology sector.
New Sales Opportunity The launch of REZLIDHIA, an innovative drug by Rigel Pharmaceuticals for acute myeloid leukemia treatment, listed in NCCN Guidelines, opens up new sales opportunities and market penetration in the oncology space.
International Market Entry With Rigel Pharmaceuticals developing and commercializing TAVALISSE in China through a strategic partnership, it signifies a doorway to the Asian market, paving the way for potential sales growth in a new geographic region.
Investment Partnership Receiving investments like $198,000 from SG Americas Securities LLC showcases investor confidence in Rigel Pharmaceuticals, presenting an opportunity to leverage this financial support for further business expansion and sales initiatives.
Key Leadership Addition Appointment of Lisa Rojkjaer as Chief Medical Officer brings in expertise to drive clinical development and regulatory strategies, potentially enhancing product approval processes and creating avenues for increased sales and market share.
Rigel Pharmaceuticals Inc. uses 8 technology products and services including Google Analytics, Commvault, jQuery Migrate, and more. Explore Rigel Pharmaceuticals Inc.'s tech stack below.
| Rigel Pharmaceuticals Inc. Email Formats | Percentage |
| FLast@rigel.com | 95% |
| FirstL@rigel.com | 3% |
| FirstLast@rigel.com | 1% |
| Last@rigel.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients hematologic disorders, cancer and rare immune diseases.
Company Overview
Media & News
Funding & FinancialsRigel Pharmaceuticals Inc. has raised a total of $17M of funding over 4 rounds. Their latest funding round was raised on Jan 29, 2021 in the amount of $17M.
Rigel Pharmaceuticals Inc.'s revenue is in the range of $10M$50M
Funding & FinancialsRigel Pharmaceuticals Inc. has raised a total of $17M of funding over 4 rounds. Their latest funding round was raised on Jan 29, 2021 in the amount of $17M.
Rigel Pharmaceuticals Inc.'s revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com